IPP Bureau
Novartis bags Phase III win for Remibrutinib in chronic inducible urticaria
By IPP Bureau - February 20, 2026
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
BIOEMTECH & NorthStar strike deal to boost access to critical Actinium-225 for preclinical research
By IPP Bureau - February 20, 2026
The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies
Johnson & Johnson bags FDA nod for monthly RYBREVANT FASPRO dosing in advanced lung cancer
By IPP Bureau - February 20, 2026
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Axol Bioscience acquires ophthalmology business from Newcells Biotech
By IPP Bureau - February 19, 2026
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
BioAsia 2026 cements Telangana’s global leadership in TechBio and life sciences
By IPP Bureau - February 19, 2026
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment
By IPP Bureau - February 19, 2026
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
Dr Reddy’s enters hormone replacement therapy market with landmark brand acquisition
By IPP Bureau - February 19, 2026
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
Merck, Mayo Clinic forge AI powerhouse to accelerate drug discovery
By IPP Bureau - February 19, 2026
Lilly breakthrough: Dual treatment clears skin & cuts weight in psoriasis patients
By IPP Bureau - February 19, 2026
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg
By IPP Bureau - February 19, 2026
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension
GSK announces breakthrough data showing RSV vaccine cuts hospitalizations in elderly
By IPP Bureau - February 19, 2026
The data highlights its RSV vaccine cuts hospitalizations in older adults
GSK’s Exdensur wins EU nod for severe asthma
By IPP Bureau - February 19, 2026
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
Evinova teams up with Astellas, AstraZeneca & Bristol Myers Squibb to supercharge clinical trials with AI
By IPP Bureau - February 19, 2026
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
Catalent and S.Biomedics join forces to advance groundbreaking Parkinson’s therapy
By IPP Bureau - February 19, 2026
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
